Golden Isles Development Authority Builds on Momentum Through Strategic Investment, Business Growth, and Workforce Progress

NEWS PROVIDED BY

Golden Isles Development Authority

Sep 01, 2026, 08:00 ET

SHARE THIS ARTICLE

Fiscal year 2026 brought $70 million in new investment alongside business expansion, workforce outreach, and site development that strengthened Brunswick and Glynn County's long-term economic competitiveness. 

BRUNSWICK, Ga., Sept. 1, 2026 /PRNewswire/ -- The Golden Isles Development Authority (GIDA) has released its 2026 Year in Review, highlighting another year of strategic progress as the organization attracted investment, supported existing industries, strengthened workforce initiatives, and advanced key development sites across Brunswick and Glynn County.

During fiscal year 2026, GIDA helped facilitate $70 million in new capital investment and 91 new jobs; aided the expansion of five existing businesses; expanded workforce outreach efforts that engaged approximately 6,000 educators, students, parents, and community members; and advanced industrial sites that will help position the Golden Isles for future business growth.

"This year, we continued bolstering the businesses that already call Glynn County home while attracting new investment and preparing sites for future opportunities," said Ryan Moore, President & CEO of the Golden Isles Development Authority. "Combined with our ongoing workforce initiatives, those efforts are helping to build the foundation for sustained economic growth across the Golden Isles."

GIDA's highlights from the fiscal year include:

Facilitated $70 million in new capital investment, creating 91 new jobs through Project Parrot, continued investment at Hillpointe, and other business activity.

Supported the expansion of five existing Glynn County employers: Troy Acoustics, Jered, Quaker City Plating, Brewer Technologies, and RSW.

Reached approximately 6,000 educators, parents, students, and community members through Keep Glynn Running workforce initiatives.

Increased visits to GIDA's available-property web pages by 144% and digital engagement across platforms by 38%, helping showcase Glynn County to prospective businesses and site selectors.

Advanced Mallard Industrial Park, expanding opportunities for future industrial development, along with construction of a new industrial entrance serving the Georgia Breakbulk Logistics Park.

Partnered with many of Glynn County's largest employers, including GP Cellulose, King and Prince Seafood, Gulfstream, Rich Products, and International Auto Processing.

The organization also exceeded its goal for consultant-driven business development, with 38% of project opportunities originating through site selection consultants and brokers, reflecting GIDA's investment in relationship-building and national business recruitment efforts.

Beyond business attraction, GIDA continued developing a broader workforce strategy to help employers recruit and retain talent while supporting the region's long-term economic growth.

"Our success is built on collaboration," said Bill Dawson, Chair of the GIDA Board of Governors and retired General Manager of Operations, Georgia Ports Authority. "Every project, every partnership, and every workforce initiative represents people working together to strengthen the Golden Isles. The accomplishments of fiscal year 2026 demonstrate GIDA's ongoing commitment to helping businesses and communities thrive."

For more information about GIDA's initiatives or to read the full 2026 Year in Review, visit https://goldenislesdev.com/report/.

About the Golden Isles Development Authority

The Development Authority is the organization that is tasked with the creation of jobs and investment in Glynn County through the retention, expansion, and attraction of business and industry. Its mission is to ensure that Brunswick and Glynn County have a strong business climate that encourages the growth of existing industries and is an attractive location for prospective businesses.

SOURCE Golden Isles Development Authority

21%

more press release views with 

Request a Demo

Sentric Specialty and Neumann Advisory Services Announce Strategic Partnership for Product Safety Risk Management

NEWS PROVIDED BY

Sentric Specialty

Sep 01, 2026, 08:00 ET

SHARE THIS ARTICLE

Exclusive relationship pairs Sentric Specialty's coverage for food and beverage companies with NAS's real-world product safety expertise to support clients before and after an event

NOVATO, Calif., Aug. 28, 2026 /PRNewswire/ -- Sentric Specialty today announced an exclusive strategic relationship with Neumann Advisory Services, LLC (NAS), a nationally recognized product safety and risk management advisory firm. Through this relationship, Sentric Specialty's eligible policyholders will receive exclusive access to NAS's specialized expertise in product safety, regulatory compliance, food safety, recall preparedness, crisis management and response, and enterprise risk reduction.

The relationship reflects a shared commitment to helping food and beverage manufacturers proactively identify, assess, and mitigate product-related risks before they become costly incidents, insurance claims, or public safety risks. By combining industry-leading underwriting capabilities with practical operational and regulatory expertise, Sentric Specialty is expanding the value it delivers well beyond traditional insurance coverage.

"Insurance is most valuable when it helps prevent losses, not simply respond to them," said Florian Beerli, CEO of Sentric Specialty. "This exclusive relationship allows us to offer our policyholders access to specialized expertise that helps strengthen risk management programs, improve operational resilience, and reduce both the frequency and severity of product-related events."

"Organizations today face increasingly complex product safety, regulatory, and supply chain risks," said Melanie Neumann, President of NAS. "Together with Sentric Specialty, we are creating a unique offering that gives policyholders access to practical, real-world guidance from experienced industry professionals before, during, and after critical events."

Unlike traditional insurance programs that primarily respond after a loss has occurred, this exclusive relationship integrates proactive risk management with insurance protection. Eligible policyholders gain access to experienced advisors who help identify vulnerabilities, strengthen preventive controls, improve recall readiness, and enhance organizational resilience, helping reduce operational disruptions, protect brand reputation, and lower the overall cost of risk. The result is a more comprehensive approach to product safety risk management that helps organizations prevent incidents whenever possible and respond more effectively when they occur. Brokers with questions can contact Nick Keyser, Global Head of Distribution, at nkeyser@sentricins.com.

About Sentric Specialty 

Sentric Specialty is a specialty managing general agent focused on niche and emerging risks. Built on the Balavant platform, Sentric gives brokers direct access to experienced underwriters who understand complex risks and are committed to delivering thoughtful, responsive service. Sentric Specialty's inaugural product, Manufacturing Defect Protection, closes a long-standing gap by expanding Product Recall coverage to include Manufacturers E&O. For more information, visit sentricins.com.

About Neumann Advisory Services, LLC 

NAS is a specialized product safety and enterprise risk management advisory firm providing strategic consulting, regulatory guidance, incident/crisis management, recall preparedness, and technical risk reduction services to manufacturers and consumer products companies. The firm's experienced professionals help organizations strengthen preventive controls, improve operational resilience, and protect consumers, brands, and business continuity. For more information, visit neumannadvisory.com.

SOURCE Sentric Specialty

21%

more press release views with 

Request a Demo

Kalohexis Appoints Garry Menzel, Ph.D., to Board of Directors

NEWS PROVIDED BY

Kalohexis

Sep 01, 2026, 08:00 ET

SHARE THIS ARTICLE

Dr. Menzel brings over 30 years of global healthcare executive leadership with broad experience in building successful companies

NORTHBROOK, Ill., Sept. 1, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Garry Menzel, Ph.D., to its Board of Directors.

"Garry is a seasoned global healthcare executive with a very strong track record in advising and leading successful life sciences companies," said Russell Potterfield, Chief Executive Officer of Kalohexis. "He has used those skills in many situations that are relevant for Kalohexis and proven himself adept at integrating effectively with different teams to produce lifesaving therapies. I look forward to working with him as we advance our differentiated melanocortin-based approach to restoring metabolic balance."

Dr. Menzel is a senior global healthcare executive and investor with a diverse background in science, strategy, finance and operations. He currently serves as an Operating Partner at Global Healthcare Opportunities (GHO) Capital, Europe's leading healthcare specialist private equity firm. Previously, he was the President and Chief Executive Officer of oncology company TCR² Therapeutics, which he led from concept to clinical success while raising more than $500 million before its strategic merger with Adaptimmune in 2023. He also co-founded Black Diamond Therapeutics, a Fierce 15-winning clinical-stage precision oncology company and continues to serve on its Board of Directors where he is Chair of the Audit Committee. Prior executive leadership roles included serving as Chief Financial Officer of Fortune 500 company DaVita HealthCare Partners and as Chief Operating Officer of Regulus Therapeutics, which was sold to Novartis for $1.7 billion. Recently, he served on the Board of genetic disease company Stoke Therapeutics.

Dr. Menzel began his life sciences career in an advisory role, first as a strategy consultant with Bain then as an investment banker with Goldman Sachs and Credit Suisse where he led their global biotechnology franchises. During his investment banking tenure, Dr. Menzel worked on more than $100 billion in transactions, including many that were transformative for the industry. These ranged from IPOs to M&A.

"Kalohexis has the opportunity to transform the treatment of obesity with 710GO by enabling healthier, more durable weight loss in general obesity without the limitations seen with incretins, such as loss of lean muscle mass and weight rebound following treatment cessation," said Dr. Menzel. "I am passionate about developing novel therapies and look forward to working with Kalohexis as the team advances its melanocortin-based pipeline, which also includes mifomelatide for cancer cachexia, where there are currently no FDA-approved treatment options."

Dr. Menzel received his Ph.D. in Biochemistry and Molecular Biology from St. John's College, University of Cambridge, his M.B.A. from the Stanford University Graduate School of Business, and his B.Sc. with Honors in Biochemistry from Imperial College of Science & Technology, London.

About Kalohexis, Inc. 

Kalohexis, Inc. is a clinical-stage biotechnology company, spun out of Endevica Bio in March 2026, shaping the next era of metabolic disease care by harnessing the melanocortin system, the body's natural regulator of metabolic homeostasis, to help people live healthier lives. Kalohexis' therapeutic peptide candidates are designed to safely and effectively drug central melanocortin-3 and -4 receptors (MC3R/MC4R) to treat many metabolic disorders. Kalohexis' lead pipeline programs are 710GO, an oral dual MC3R/MC4R agonist to induce healthier, more durable weight loss in general obesity, and mifomelatide, a dual MC3R/MC4R antagonist to treat cachexia in patients with advanced cancers. For more information, visit www.kalohexis.com or follow us on LinkedIn and X. 

Investor and Media Contact:

Argot Partners

kalohexis@argotpartners.com

SOURCE Kalohexis

21%

more press release views with 

Request a Demo

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

NEWS PROVIDED BY

Bausch Health Companies Inc.

Sep 01, 2026, 08:01 ET

SHARE THIS ARTICLE

The next generation in skin resurfacing technology is available to Australian health care practitioners beginning September 1, 2026

LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX® in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning September 1, 2026.

Building on more than 20 years of innovation in skin resurfacing, Fraxel FTX represents the next generation of the Fraxel® platform. Designed to support treatment precision, workflow efficiency and patient comfort, Fraxel FTX brings together trusted technology with meaningful refinements for modern aesthetic practice.

"Fraxel FTX builds on the trusted technology of the Fraxel platform, combining proven performance with enhancements designed to support today's aesthetic practices," said Jiny Kim, Senior Vice President, Solta Medical, Bausch Health. "We are pleased to make this technology available in Australia and continue supporting practitioners with solutions designed to meet the evolving needs of their patients."

Fraxel is one of the highly recognized treatments in skin resurfacing and may be used to address a range of common skin concerns, including the appearance of fine lines and wrinkles, lentigos and ephelides, acne scars and surgical scars, dyschromia including melasma, and actinic keratosis. With Fraxel FTX, Solta Medical continues to build on that clinical heritage with a system designed to support consistent treatment delivery across superficial and deeper skin layers.

"Fraxel has long been recognized by practitioners for its precision, versatility and clinical heritage," said Alistair McKeon, General Manager, Solta, ANZ & SEA. "With Fraxel FTX, we are bringing Australian healthcare practitioners an updated platform that builds on that trusted foundation while supporting ease of use, treatment consistency and patient comfort in everyday practice."

Key features and benefits of Fraxel FTX

Two wavelengths, one intelligent approach: Fraxel FTX uses dual wavelengths to enable targeted treatment at different tissue depths. The 1927 nanometer wavelength targets the epidermal layer, while the 1550 nanometer wavelength penetrates into the deeper dermis while also treating the epidermis.

Precision treatment delivery: As the tip moves over the skin, the laser treats a fraction of the skin at a time, creating a large number of microscopic treatment zones in a dot-like pattern. By leaving surrounding tissue intact, the system is designed to support rapid healing.

Intelligent Optical Tracking™ with AccuTRAC®: The patented optical system calculates hand motion during treatment to help support proper skin contact, dosimetry and uniform delivery, while making laser firing more efficient.

Redesigned ergonomic handpiece: The handpiece features a 20% reduction in circumference and weight, and is designed to improve field of view, treatment precision and ease of handling.

Integrated cooling designed for patient comfort: Cooling is routed through the handpiece and tip directly to the skin, with airflow directed at the treatment area.

Refreshed treatment interface: The guided user interface is designed to facilitate treatment settings, total and estimated energy visibility, handpiece speed, and color change between wavelengths.

Modern console design: Fraxel FTX features an updated console with an integrated arm and cable assembly, in line with the Solta product family.

Fraxel FTX is a highly versatile and recognized treatment in aesthetics, designed to address five common skin concerns contributing to skin health: the appearance of fine lines and wrinkles, lentigos and ephelides, acne scars and surgical scars, dyschromia including melasma, and actinic keratosis.

Solta Medical supports health care practitioners with more than technology alone. In Australia and New Zealand, that includes clinical education, practical training and ongoing business support designed to help practitioners build confidence in treatment delivery and support long-term practice growth.

To learn more, visit soltamedical.com.au.

INDICATIONS

The Fraxel FTX® Laser System is indicated for:

Fraxel® 1550 nm wavelength is indicated for dermatological procedures requiring the coagulation of soft tissue; skin resurfacing procedures; treatment of dyschromia and cutaneous lesions, such as, but not limited to lentigos, solar lentigos, actinic keratosis, and melasma; and treatment of periorbital wrinkles, acne scars, and surgical scars. 

Fraxel® 1927 nm wavelength is indicated for dermatological procedures requiring the coagulation of soft tissue; treatment of actinic keratosis; treatment of pigmented lesions, specifically lentigos, solar lentigos, and ephelides.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not use on any patient who is ineligible for general surgery.

Pre-screening should include, but not be limited to:

Predisposition to keloid formation or excessive scarring.

Changes following surgery.

Skin indentations and textural changes following surgery.

Systemic steroids (e.g. prednisone, dexamethasone), which should be rigorously avoided prior to and throughout the course of treatment.

Patients undergoing isotretinoin acne treatment or with drugs in a similar class.

Medical judgement should be used when treating patients with a predisposition to post inflammatory hyperpigmentation (PIH).

Warnings and Cautions

Protective eyewear or goggles should be worn by any patient, operator and assistant.

Medical judgement should be used when treating patients with certain medical conditions.

Improper use of Fraxel® may cause personal injury or damage to the system.

Adverse Events

The following may be associated with Fraxel® laser treatment: Blistering and burns; Temporary or permanent skin discoloration; Eye injury; Infection; Keloid formation; Prolonged redness; Scarring; Delayed wound healing / skin textural changes and Temporary bruising.

The Fraxel FTX® Laser System is Rx Only. See the Operator Manual for detailed directions, proper use, and full risk and safety information. For additional product information see www.fraxel.com/hcp. 

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. To learn more about the Fraxel FTX® and how it can benefit your practice, contact Solta Medical.

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our aesthetic business, Solta Medical, is a global leader in the aesthetics market, whose vision is to develop and support trusted aesthetic brands that provide value to our customers and patients. More information about Solta Medical can be found at www.solta.com. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. 

Forward-looking Statements

This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Fraxel® is a trademark of Solta Medical, Inc. or its affiliates.

©2026 Solta Medical, Inc. or its affiliates

Investor Contact:

Media Contact:

Garen Sarafian

Katie Savastano

ir@bauschhealth.com

 corporate.communications@bauschhealth.com

(877) 281-6642 (toll free)

(908) 569-3692

BHC-PRODUCTS

SOURCE Bausch Health Companies Inc.

21%

more press release views with 

Request a Demo

CITGO Strengthens Lake Charles Refinery's Future with $310 Million Project

NEWS PROVIDED BY

CITGO Petroleum Corporation

Sep 01, 2026, 08:00 ET

SHARE THIS ARTICLE

Investment supports long-term refinery viability, regional economic stability and reliable U.S. fuel supply

HOUSTON, Sept. 1, 2026 /PRNewswire/ -- CITGO Petroleum Corporation is advancing its Lake Charles Refinery Depentanizer Project, a $310 million investment that supports the long-term competitiveness of one of the nation's largest and most complex refineries.

The project will add new facilities and equipment to improve naphtha upgrading capabilities at the Lake Charles Refinery by converting lower-value streams into higher-value gasoline blend components. Once complete, the project is expected to increase refinery flexibility and enhance CITGO's ability to meet continued U.S. demand for reliable transportation fuels.

"The Depentanizer Project reflects CITGO's commitment to disciplined investments that enhance the strength and resilience of our refining system," said Edgar Rincon, CITGO Executive Vice President and Chief Operating Officer. "It also reinforces the strategic importance of the Lake Charles Refinery to our company, our customers and the broader U.S. energy market."

For Southwest Louisiana, the investment represents more than an operational upgrade. It reinforces the long-term future of the Lake Charles Refinery, supports the refinery's existing workforce and creates additional contract work during construction. The project also extends opportunities for local suppliers and service providers that are part of the region's energy economy.

"For generations, the Lake Charles Refinery has helped power Southwest Louisiana's economy and identity," said Sterling Neblett, CITGO Lake Charles Refinery Vice President and General Manager. "This project reflects our confidence in the refinery's future and our commitment to supporting the people, businesses and communities connected to its success."

The Lake Charles Refinery has deep roots in Louisiana. The facility began operations in 1944, originally supporting the country's need for aviation fuel during World War II. Over the decades, it has grown into CITGO's largest refinery and a cornerstone of the company's refining network, producing gasoline, diesel, jet fuel, petrochemicals and other products used by consumers and industries across the country.

Located along the Calcasieu Ship Channel, the refinery is strategically positioned to receive and process a diverse slate of crude oils and move refined products to key markets through pipelines, marine access and other logistics channels. The Depentanizer Project builds on that strong asset base by enhancing Lake Charles' ability to process domestic light crude and produce additional gasoline components.

The project is expected to be operational in 2029. CITGO will continue to work with employees, contractors and local stakeholders as engineering, construction and commissioning activities advance.

About CITGO

CITGO Petroleum Corporation is a recognized leader in the refining industry and operates under the well-known CITGO brand. CITGO owns and operates three refineries located in Lake Charles, La.; Lemont, Ill.; and Corpus Christi, Texas, and wholly and/or jointly owns 43 active terminals, eight pipelines and three lubricants blending and packaging plants. With approximately 3,300 employees and a combined crude capacity of approximately 829,000 barrels-per-day (bpd), CITGO ranks as the fifth largest and is one of the most complex independent refiners in the United States. CITGO transports and markets transportation fuels, lubricants, petrochemicals and other industrial products, and supplies a network of approximately 4,000 locally owned and independently operated branded retail outlets. CITGO Petroleum Corporation is owned by CITGO Holding, Inc.

SOURCE CITGO Petroleum Corporation

21%

more press release views with 

Request a Demo

Ascend Analytics Surpasses 5 GW of Battery Storage Assets Managed with SmartBidder

NEWS PROVIDED BY

Ascend Analytics

Sep 01, 2026, 08:00 ET

SHARE THIS ARTICLE

Ascend is the largest independent provider of bid optimization to the U.S. battery storage market, with more than 30 customers and assets spanning ERCOT, CAISO and PJM

BOULDER, Colo., Sept. 1, 2026 /PRNewswire/ -- Ascend Analytics ("Ascend"), the leading provider of market intelligence and analytics solutions for the power industry, today announced that its SmartBidder™ platform now optimizes more than 5.2 gigawatts (GW) of operating battery energy storage capacity in U.S. wholesale power markets. The milestone reflects live, commercially operating assets under active management and further establishes Ascend as the largest independent provider of bid optimization services to the U.S. storage market.

The operating portfolio spans three markets and more than 30 customers, with approximately 4 GW under management in ERCOT, 1 GW in CAISO and 200 megawatts (MW) in PJM. Ascend crossed the 5 GW threshold in the second quarter of 2026 with the onboarding of assets for California Community Power, a Joint Power Agency, and San Diego Community Power, a Community Choice Aggregator (CCA), that have contracted storage capacity to serve loads they manage directly or on behalf of their members.

"Five gigawatts is a significant milestone and tells part of the story. What is equally impressive is the breadth of assets behind that number. SmartBidder optimizes everything from 3-megawatt batteries to 300-megawatt batteries, one-hour to eight-hour durations, standalone, hybrid and resources co-located with wind and solar facilities, operating in three ISOs under unique market rules," said Michael Huisenga, Managing Director, Bid Optimization at Ascend Analytics. "Load-serving entities, in particular, are taking on market exposure with a new asset class they may not have managed before. Leveraging the experience of the SmartBidder solution and our team of experts to deploy customized, risk-constrained, automated bidding strategies gives them the tools to achieve their portfolio objectives."

Longer-duration storage is a growing share of Ascend's portfolio, with SmartBidder managing one of the first eight-hour duration batteries to reach commercial operation in CAISO, as well as one of the first four-hour duration batteries to come online in ERCOT. Ascend has also been an early mover in PJM, where it has optimized storage for more than two years and now manages 200 MW of operating capacity. Most of the operating storage fleet in PJM are short duration (1hr) batteries that were deployed to provide frequency regulation service only. Ascend is one of very few providers running bid optimization for longer-duration resources (2-4hrs) that provide frequency regulation, reserves, and energy arbitrage services, while adapting the bidding algorithms to successive market rule changes along the way.

"Storage is becoming the balancing resource for the U.S. power system, and the economics of every one of these assets come down to how well it is bid into the market," said Matt Tormollen, Chief Executive Officer of Ascend Analytics. "Ascend's forecasts sit at the foundation of more than $50 billion in project financing assessments. Managing more than 5 gigawatts of operating storage means we also see how those assets perform hour by hour, in real markets, under real conditions. That lifecycle, from long-term valuation through to real-time dispatch, is why utilities and power producers increasingly choose Ascend to help navigate rapidly shifting power markets."

SmartBidder combines probabilistic short-term price forecasting with configurable opportunity cost-based bid optimization in one seamless automated solution, allowing storage operators to capture value across day-ahead and real-time markets for energy and ancillary services, while managing state of charge, degradation and contractual constraints.

Additional information can be found at https://www.ascendanalytics.com/solutions/smartbidder. 

About Ascend Analytics

Ascend Analytics is the leading provider of market intelligence and analytics solutions for the power industry. The company's offerings enable decision makers in power supply, procurement, and investment markets to plan, operate, monetize, and manage risk for renewable energy and storage assets. From real-time to 30-year horizons, their forecasts and insights are at the foundation of over $50 billion in project financing assessments. Ascend provides energy market stakeholders with the clarity and confidence to successfully navigate the rapidly shifting energy landscape.

SOURCE Ascend Analytics

21%

more press release views with 

Request a Demo

Ribbon Bolsters Its Market-Leading Critical Infrastructure Portfolio USA - English

NEWS PROVIDED BY

Ribbon Communications Inc.

Sep 01, 2026, 08:00 ET

SHARE THIS ARTICLE

New generation of routers delivers expanded routing, automation, security and synchronization capabilities

PLANO, Texas, Sept. 1, 2026 /PRNewswire/ -- Ribbon Communications Inc. (Nasdaq: RBBN), a global leader in real-time communications technology, IP routing, and optical networking solutions, today announced the expansion of its critical infrastructure portfolio. The portfolio is designed to help utilities modernize increasingly complex operational networks while maintaining the reliability, security and deterministic performance required for essential services. Ribbon's experience spans hundreds of thousands of deployed network elements across the world, supporting some of the industry's most complex networks.

Utilities face growing pressure to modernize the grid, integrate distributed energy resources, improve reliability and strengthen cybersecurity. Meeting these requirements demands communications networks that support both legacy operational technologies and next-generation digital applications. Ribbon's market-leading critical infrastructure portfolio enables utilities to evolve confidently and at their own pace while preserving operational continuity and protecting mission-critical services.

"Utilities must modernize their networks, strengthen cyber resilience and support new digital grid initiatives without disrupting core operations," said Sam Bucci, EVP and COO at Ribbon. "Our expanded portfolio enables them to bridge legacy and next-generation requirements on a single, modern platform."

The new NPT 1022M and NPT 2104 build on the proven capabilities of existing platforms including the NPT 1012D and NPT 2714. Combined with Ribbon's IP rNOS routing software, optical networking portfolio and Muse multilayer automation platform (MAP), these technologies further strengthen Ribbon's ability to support the converged IT/OT communications networks that underpin modern utility operations.

Designed to address the demanding requirements of utility network modernization, Ribbon's solutions support teleprotection, SCADA, operational voice, always-on OT operations, deterministic packet transport (MPLS-TP, SR-TE), scalable IP/MPLS networking and class D timing for precise frequency and time synchronization across the grid.

These capabilities enable utilities to introduce advanced monitoring, automation, video, distributed energy resource management and smart grid analytics while modernizing their communications infrastructure without compromising operational continuity.

Ribbon's robust features includes:

Muse, which delivers critical infrastructure-focused automation and AI-enabled capabilities that simplify deployment, operations and management.

Advanced circuit emulation legacy for 64 kbit/s PCM services alongside advanced 100GbE and 400GbE interfaces

Built-in quantum-safe security and MACsec

IEC 61850 compliance and IEEE 1613 class B certification

Fully integrated IPoDWDM

"These innovations provide a strong foundation for utilities transitioning from TDM to IP-MPLS and segment routing architectures while preserving the reliability and performance essential to their operations," Mr. Bucci added. "They enable utilities to support both legacy and modern services on a common architecture while maintaining operational continuity."

About Ribbon

Ribbon Communications (Nasdaq: RBBN) is a global provider of voice communications software, IP routing, and optical networking to mobile and wireline service providers, enterprises, critical infrastructure and defense sectors. We support our customers' Path to Autonomous Networks by leveraging the latest AIOps automation platforms and Agentic AI technologies, helping them deliver better customer experiences, reduce operational costs, and achieve sustainable growth. To learn more about Ribbon, visit rbbn.com.

Important Information Regarding Forward-Looking Statements

The information in this release contains forward-looking statements regarding future events that involve risks and uncertainties. All statements other than statements of historical facts contained in this release, including those regarding the expected benefits from use of Ribbon Communication's products, are forward-looking statements. The actual results of Ribbon Communications may differ materially from those contemplated by the forward-looking statements. For further information regarding risks and uncertainties associated with Ribbon Communications' business, please refer to the "Risk Factors" section of Ribbon Communications' most recent annual or quarterly report filed with the SEC. Any forward-looking statements represent Ribbon Communications' views only as of the date on which such statement is made and should not be relied upon as representing Ribbon Communications' views as of any subsequent date. While Ribbon Communications may elect to update forward-looking statements at some point, Ribbon Communications specifically disclaims any obligation to do so.

Investor Contact

+1 (978) 614-8050

ir@rbbn.com

Media Contact

Catherine Berthier

+1 (646) 741-1974

cberthier@rbbn.com 

SOURCE Ribbon Communications Inc.

21%

more press release views with 

Request a Demo

SmartConnect and Benepicks Unite to Eliminate the ICHRA "Medicare Cliff"

NEWS PROVIDED BY

SmartConnect Medicare Business Solutions

Sep 01, 2026, 08:00 ET

SHARE THIS ARTICLE

Bridging the gap between ICHRA and Medicare: Two industry leaders combine tax-free health allowances and zero-cost advocacy to combat rising healthcare costs for the aging workforce. 

The Problem: Standard ICHRA platforms lack Medicare integration, leaving aging workers to navigate complex transitions alone while HR teams face administrative gridlock.

The Solution: SmartConnect's "Medicare Intelligence Layer" is now embedded into Benepicks' human-centered ICHRA platform, providing real-time, licensed agent support.

The Impact: Employees unlock zero-cost Medicare advocacy, lower deductibles, and richer coverage, while organizations eliminate HR headaches and average a 15% reduction in healthcare spending according to recent data.

KANSAS CITY, Mo. and SEATTLE, Sept. 1, 2026 /PRNewswire/ -- SmartConnect and Benepicks today announced a nationwide partnership to eliminate one of the most critical friction points of ICHRA platforms: the Medicare transition for 65+ employees.

As rising healthcare costs accelerate employer adoption of ICHRAs, a major structural gap has emerged. Many platforms are built for individual Marketplace insurance, leaving Medicare-eligible employees to navigate complex decisions on their own. This gap often results in costly healthcare mistakes for workers, administrative paralysis for HR departments, and client friction for benefits brokers and ICHRA administrators.

The ICHRA-Medicare gap is officially closed, setting a new industry standard of support for America's aging workforce.

Post this

This partnership bridges the gap by embedding SmartConnect's dedicated "Medicare Intelligence Layer" directly into Benepicks' human-centered ICHRA platform.

"The old way is broken," said Andrew Lydens, CEO of Benepicks. "Handing a 65-year-old a stack of Medicare mail and a deadline is a poor way to thank someone for twenty years of work. Now every Medicare-eligible employee gets a real person to call and tax-free dollars that help pay for the plan they choose."

Medicare-eligible employees on the Benepicks platform are now seamlessly introduced to SmartConnect's purpose-built ecosystem. Employees receive personalized, unbiased Medicare consultations from agents licensed in all 50 states. Consultations evaluate each individual's specific doctors, prescriptions, and financial goals.

With broad visibility across Medicare plan options, SmartConnect handles the enrollment details, transition logistics, and ongoing lifetime policy advocacy, ensuring the employee feels supported from day one and has a Medicare partner for life. Employees can then use their tax-free Benepicks ICHRA allowance toward their selected plan premiums and HR has a trusted partner for this complex topic.

The alliance combines two health benefit heavyweights with deep national reach who expect to transform the healthcare transition experience for thousands of aging workers while securing predictable, optimized costs for their employers.

"We are absolutely thrilled to be trailblazing the intersection of Medicare and ICHRA alongside Benepicks," said Michael Celi, General Manager & SVP of SmartConnect. "By integrating our Medicare solution directly with Benepicks' innovative experience, we are delivering a market-leading solution that optimizes the employer's benefits strategy while giving employees the ultimate peace of mind."

Beyond operational ease, the financial benefits are substantial. Transitioning 65+ employees to tailored Medicare plans via an ICHRA allowance routinely unlocks lower deductibles and richer coverage for workers.

Enterprise leaders and HR Directors seeking to optimize healthcare spend can learn more by visiting Benepicks.com. Employee benefits brokers, TPAs, and organizations looking to incorporate Medicare guidance into their offerings can connect at SmartConnectPlan.com.

About SmartConnect

SmartConnect Medicare Business Solutions is responsible for managing and executing dedicated Medicare support across thousands of corporate partnerships. As a business unit of Spring Venture Group, they provide industry-leading Medicare education and enrollment solutions. As a broader organization, Spring Venture Group operates across multiple brands with 1,100 employees and stands as a national leader in Medicare distribution.

About Benepicks

Benepicks is a modern ICHRA technology platform built on a human-first service model. Powered by a dedicated network of 120+ licensed agents, Benepicks combines intuitive digital shopping, automated payroll integrations, live webinars, and ancillary benefit support with year-round member advocacy. With built-in Medicare eligibility detection and agent routing, Benepicks delivers flexible, high-touch health reimbursement solutions for forward-thinking employers nationwide.

Media Contacts:

SmartConnect Media Relations: businessdevelopment@smartmatch.com 

Benepicks Media Relations: media@benepicks.com 

SOURCE SmartConnect Medicare Business Solutions

21%

more press release views with 

Request a Demo

NIVEA MEN Introduces New Liquid Moisturizers, Bringing Lightweight Care to Men's Daily Routines

NEWS PROVIDED BY

NIVEA MEN

Sep 01, 2026, 07:57 ET

SHARE THIS ARTICLE

Our first liquid moisturizer in the men's skincare category, this innovation delivers hydrating and soothing care in ultra-lightweight formulas for sensitive and dry skin.

STAMFORD, Conn., Sept. 1, 2026 /PRNewswire/ -- NIVEA MEN, the leading brand in men's face care, today announced the launch of their first-ever Liquid Moisturizer line. The two dermatologically tested formulas are designed for daily use and tailored to different skin needs: Sensitive Liquid Moisturizer soothes and comforts sensitive skin, while Maximum Hydration Liquid Moisturizer delivers lightweight hydration for dry, rough skin. Together, they give men what their skin needs in a lighter, easier format than a traditional moisturizer.

NIVEA Men Liquid Moisturizers

"At NIVEA MEN, we understand that consistency is key to caring for skin, and products need to fit naturally into men's everyday routines," said Lauren Lynch, marketing director, NIVEA MEN, Beiersdorf Inc. "Our new Liquid Moisturizers offer a modern, lightweight approach to daily care, helping men find the formula that best meets their individual skin needs."

The launch reflects Beiersdorf's broader commitment to developing skin care solutions that meet consumers across a range of needs, preferences and routines.

"At Beiersdorf, we combine deep skin care expertise with a constant focus on evolving consumer needs," said Andrea Mondoni, General Manager, Beiersdorf Inc. "NIVEA MEN Liquid Moisturizers are an example of how we continue to bring meaningful innovation to market, expanding our portfolio with solutions that deliver relevant benefits and support the long-term growth of our brands."

The NIVEA MEN Liquid Moisturizer line is available in two easy-to-use formulas, designed to address specific skin needs and simplify a daily grooming routine:

NIVEA MEN Sensitive Liquid Moisturizer: Formulated for normal to dry, sensitive skin, this fragrance-free formula provides smooth hydration that soothes and comforts skin on contact. It is enriched with a 5% Soothing Complex featuring Ceramide and Zinc PCA, plus Glycerin and Provitamin B5, a Smart Barrier Technology, and gentle skin-supporting formula. With regular use, 98% of men said the formula was suitable for their sensitive skin, while 90% said it soothed their skin.*

NIVEA MEN Maximum Hydration Liquid Moisturizer: Designed for normal to dry skin, this crystal-clear formula delivers weightless hydration that absorbs instantly. Enriched with a 5% Hydrating Complex featuring hyaluronic acid and vitamins, it immediately smooths dry, rough skin texture and leaves skin refreshed, healthy-looking and comfortable. The formula has a light masculine fragrance With regular use, 98% of men said the formula left their skin feeling refreshed and invigorated.**.

The NIVEA MEN Liquid Moisturizer line will be available on Amazon beginning in September 2026, with nationwide retail availability anticipated in 2027. For more information, follow NIVEA MEN on Instagram, Facebook and TikTok, or visit www.niveausa.com/products/men.

About NIVEA MEN

NIVEA MEN is a global leader in men's skin care, offering a comprehensive range of products designed to support men's grooming and skin care needs. Backed by more than a century of Beiersdorf skin care expertise, the brand combines innovative formulations with trusted efficacy to help men care for their skin every day. The portfolio includes face care, shaving and body care products available in markets worldwide.

About Beiersdorf

Beiersdorf Inc is the North American affiliate of Beiersdorf AG, which has stood for innovative, high-quality skincare products for over 140 years. The company's portfolio of international brands includes Aquaphor, Eucerin, NIVEA, Coppertone, La Prairie and Chantecaille. Learn more at www.beiersdorf.com.

*Self-assessment of 41 men, 2025

**Self-assessment of 42 men, 2025

Media Contact:

NIVEAMEN@mbooth.com 

SOURCE NIVEA MEN

21%

more press release views with 

Request a Demo

Organizations with trustworthy AI practices are 15 times more likely to see strong ROI, per study findings

NEWS PROVIDED BY

SAS

Sep 01, 2026, 07:57 ET

SHARE THIS ARTICLE

Employees override AI they don't understand, and it's challenging organizations seeking AI return

The number one reason employees override AI in the field? When AI can't explain a decision it's made.

Most organizations still lack the data foundation needed to make AI trustworthy and profitable.

CARY, N.C., Sept. 1, 2026 /PRNewswire/ -- A new SAS report with research insights by IDC uncovers what's powering the organizations winning the race to profit from their AI investments: embracing trustworthy AI measures. Organizations applying trustworthy AI practices were 15 times more likely to report strong return on investment (ROI) from their AI projects.

Orgs with trustworthy AI practices are 15 times more likely to see strong ROI, per a new SAS report.

Post this

Organizations embracing trustworthy AI measures are winning the race to achieve AI ROI.

As identified in the second annual Data and AI Impact Report: The New Economics of Trust, organizations with the strongest governance, data quality and auditability practices – a comparatively small market segment – consistently outperformed peers, reporting at least double the ROI from AI deployments. Fewer than one in 20 trustworthy AI 'laggard' organizations reported the same.

"When AI works, it's incredibly impactful," said Bryan Harris, CTO at SAS. "However, it is well documented that state-of-the-art agents can have error rates that exceed 25% on complex tasks1 – which is unacceptable in high-stakes decision-making. In order to achieve accuracy and repeatability, organizations must embed domain expertise into agentic workflows, while keeping people at the center of governance and oversight. Organizations that do this successfully will close the trust gap and gain a competitive advantage in the market with AI."

"As AI becomes more autonomous, organizations face a new challenge: maintaining confidence in systems people don't fully understand," said Chris Marshall, Vice President at IDC. "Our findings show that stronger oversight, explainability, accountability and data foundations are becoming prerequisites for scaling AI successfully."

The report's findings span three themes:

AI that can't explain itself is a major business liability

Researchers found that at many organizations, employees are increasingly hesitant to rely on systems that may or may not be able to offer correct output or explain how AI arrived at a final decision. As AI gains autonomy, this liability grows, making explainability crucial for success.

The report also explored a major hurdle to success in AI adoption: when employees' lack of trust in AI decisions leads them to override and make manual corrections. This only perpetuates the AI trustworthiness deficit, and can cost organizations time, productivity and profitability. When AI decision-making is only as good as the data it's based on, building a strong data foundation becomes pivotal for organizations looking to reduce override rates.

Key findings:

97.2% of users override AI-generated recommendations in at least some cases.

The number one reason employees decided to override AI, regardless of whether its output was considered correct, was when the AI could not provide an explanation behind its decision.

Trust falls from 76% for generative AI to 66% for agentic AI, highlighting growing concerns as AI systems gain more autonomy.

Trustworthy AI practices drive business success

The report exposes a widening ROI divide between organizations that prioritize trustworthy AI practices and those that do not. The findings suggest organizations gaining the most value from AI are not necessarily deploying different technologies but instead managing AI differently.

Key findings:

Organizations investing in trustworthy AI measures are 15 times more likely to report strong or high ROI on their AI projects (62% vs. 4%).

Organizations with the strongest trustworthy AI practices realize 1.85 times greater gains across 13 different business outcomes, including revenue growth, cost savings and customer experience.

85% of these AI leaders with trustworthy practices are increasing their investment in this area by more than 10% this year, actively widening the performance gap.

Too many organizations are losing time and money to weak data foundations

Most organizations are deploying AI on severely underdeveloped or outdated data and data infrastructure. Without a strong data foundation to support crucial transparency and explainability, organizations struggle to govern AI effectively and realize value.

Key findings:

Only 17.5% of enterprises have a fully optimized data infrastructure mature enough for the demands of agentic AI, which negatively impacts performance.

Organizations with an optimized data foundation are four times more likely to expect strong ROI from AI projects, and six times more likely to mandate the data quality and explainability controls necessary to build trust.

Take a deeper dive

The findings are based on a global survey of 2,699 decision-makers with knowledge of or influence over their company's data and AI initiatives. The survey was conducted across 28 countries and four focus industries: banking, insurance, life sciences and the public sector. The report highlights industry use cases and findings that demonstrate how leaders in each of these industries around the globe are approaching AI.

Key findings:

Banking leaders are going beyond compliance, treating robust AI governance as a competitive advantage and operational necessity – 85% of AI leader banks have established governance frameworks, compared to just 29% of laggards.

Forty-one percent of public sector leaders are increasing trustworthy AI investment by more than 20% in the year ahead, which is as fast as the most ambitious organizations across any industry.

23% of life sciences organizations have scaled AI company-wide – the highest of any industry.

Explore study findings and access the full report at sas.com/ai-impact.

What makes AI trustworthy?

Trustworthy AI is artificial intelligence designed to be reliable, fair, secure, up to regulatory standards, and able to clearly show how it arrived at a decision. Users and decision-makers at all levels within an organization must be able to hold an AI system to a pre-determined chain of accountability for incorrect or missing AI output. Any AI system must also be governed and proven to be in compliance with clear rules.

What makes an organization a trustworthy AI leader?

Within the study, organizations were scored out of 100 against five dimensions of trustworthy AI. The report's trustworthy AI leaders were organizations with an average total score of 80 or higher.

Each organization was scored across the following five trustworthy AI criteria.

Data quality and governance.

Model governance and oversight.

Explainability and fairness.

Responsible AI policy.

Audit and accountability.

About SAS

SAS is a global leader in data and AI, helping organizations make confident decisions with AI they can trust. For decades, SAS has set the standard for delivering software that drives meaningful impact, incorporating deep industry expertise, transparency and governance. SAS gives you THE POWER TO KNOW®.

SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration. Other brand and product names are trademarks of their respective companies. Copyright © 2026 SAS Institute Inc. All rights reserved.

Editorial Contacts:

Jennifer James, SAS

jennifer.james@sas.com 

Julia Norton, SAS

julia.norton@sas.com 

1 Sources: Stanford HAI, 2026 AI Index Report; independent AI agent benchmark evaluations.

SOURCE SAS

21%

more press release views with 

Request a Demo